# Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma

> **NCT01386398** · PHASE3 · WITHDRAWN · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC**

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** bortezomib
- **DRUG:** vorinostat
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01386398
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company withdrew interest
- **Last updated:** 2015-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01386398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01386398, "Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01386398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*